KORU Medical Systems 宣布,已撤回其在美国提交的关于Freedomedge与Phesgo组合使用的510(k)申请。此举旨在将战略重心重新聚焦于开发其他更高容量的替代分子。这一调整反映了公司对市场需求的精准把握,力求在创新药物的输送领域实现更高效的资源配置。
KORU Medical Systems 宣布,已撤回其在美国提交的关于Freedomedge与Phesgo组合使用的510(k)申请。此举旨在将战略重心重新聚焦于开发其他更高容量的替代分子。这一调整反映了公司对市场需求的精准把握,力求在创新药物的输送领域实现更高效的资源配置。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.